Results 1 to 10 of about 927,052 (258)
Characteristics of anti-IL-17/23 biologics-induced interstitial pneumonia in patients with psoriasis. [PDF]
PLoS ONE, 2021 ObjectivesAnti-IL-17/23 biologics are increasingly used to treat psoriasis. We aimed to elucidate characteristics of drug-induced interstitial pneumonia (DIIP) caused by anti-IL-17/23 biologics.MethodsWe retrospectively analyzed the clinical data of ...
Hanae Miyagawa +8 more
doaj +5 more sources
Anti-IL-17/23 Drugs for the Treatment of Moderate-to-Severe Hidradenitis Suppurativa in Patients With Concomitant Psoriasis: A Multicenter Retrospective Study [PDF]
Dermatology Practical & ConceptualIntroduction: Psoriasis and hidradenitis suppurativa (HS) are chronic inflammatory diseases with significant overlap in their immunologic pathways, which involve cytokines such as tumor necrosis factor-alfa, interleukin (IL)-17, and IL-23.
Luigi Gargiulo +17 more
doaj +2 more sources
Adverse events associated with anti-IL-17 agents for psoriasis and psoriatic arthritis: a systematic scoping review [PDF]
Frontiers in Immunology, 2023 BackgroundAnti-interleukin (IL)-17 biological agents (BAs) have significant efficacy in the treatment of psoriasis and psoriatic arthritis; however, adverse events (AEs) are common, and their safety has not been systematically evaluated.ObjectivesThe ...
Jiao Wang +16 more
doaj +2 more sources
RORγt inhibitors block both IL-17 and IL-22 conferring a potential advantage over anti-IL-17 alone to treat severe asthma [PDF]
Respiratory Research, 2021 Background RORγt is a transcription factor that enables elaboration of Th17-associated cytokines (including IL-17 and IL-22) and is proposed as a pharmacological target for severe asthma.
David Lamb +10 more
doaj +2 more sources
Rheumatoid arthritis and the proinflammatory cytokine IL-17 [PDF]
Folia Medica, 2023 Introduction: Rheumatoid arthritis (RA) is the most common inflammatory joint disease. Various proinflammatory cytokines are involved in the pathogenesis of this chronic disorder.
Pavel Selimov +8 more
doaj +3 more sources
Turkderm Turkish Archives of Dermatology and Venereology, 2022 Ixekizumab is a human immunoglobulin G4 monoclonal antibody targeting interleukin-17A. Clinical trials have reported that 82-84% of the patients using ixekizumab achieved a PASI90 response at week 12 and 85% at week 60.
İlgen Ertam Sağduyu
doaj +1 more source
Turkderm Turkish Archives of Dermatology and Venereology, 2022 Secukinumab is a human immunoglobulin G1/κ monoclonal antibody targeting interleukin-17A. In clinical trials, 77-81% of the secukinumab patients achieved a PASI75 response in 12 weeks.
Nilgün Atakan
doaj +1 more source
Dermatologic Therapy, 2022 Real‐life data about any particular treatment is very helpful for clinicians, particularly when managing a chronic disease such as psoriasis. In our study, we aimed to reflect our clinical experience during 48 weeks with an IL‐17 antagonist ixekizumab ...
Melis Gönülal +5 more
doaj +1 more source
Immunogenicity to biological drugs in psoriasis and psoriatic arthritis
Clinics, 2021 Monoclonal antibodies or fusion proteins, defined as biological drugs, have modified the natural history of numerous immune-mediated disorders, allowing the development of therapies aimed at blocking the pathophysiological pathways of the disease ...
Fernando Valenzuela, Rodrigo Flores
doaj +1 more source
Modulating asthma–COPD overlap responses with IL-17 inhibition
Frontiers in Immunology, 2023 BackgroundIL-17 is a modulator of the inflammatory response and is implicated in lung remodeling in both asthma and chronic obstructive pulmonary disease (COPD).
Leandro do Nascimento Camargo +14 more
doaj +1 more source